Tevogen Bio Files Patent For AI-Powered T Cell Vaccine Targeting Entire Viral Genome

Tevogen Bio has submitted a new patent application to the U.S. Patent and Trademark Office for its T cell-based vaccine. Unlike traditional vaccines that primarily trigger B cell responses, this innovative approach uses Tevogen’s proprietary AI-powered PredicTcell technology to identify peptides that stimulate a strong T cell response. A key advantage of this vaccine is its ability to target the entire viral genome, similar to Tevogen’s lead candidate, TVGN 489. 

Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, said, “While our T cell vaccine development currently prioritizes national security and equipping the U.S. military against biological threats, its use can be expanded to broader applications if circumstances call for it. The success of any public health measure relies on the trust and support of the people it is meant to protect, and just as I value open dialogue with our retail shareholders, I am personally committed to ensuring transparency and active public involvement throughout the development process.”

This comprehensive targeting reduces the risk of immune evasion due to viral mutations that could compromise vaccines focusing on single proteins or viral segments. Tevogen Bio explains that its vaccine development project will use existing technologies and avoids changing the previously projected revenue targets of $1 billion for its Oncology and Specialty Care divisions.